Received Dec 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
patient that received a late second dose of Shingrix; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 68-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 20-OCT-2023 with batch number 7YD42 and lot expiry 02-MAY-2027). On 10-JUN-2025, the patient received the 2nd dose of Shingrix. On 10-JUN-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: patient that received a late second dose of Shingrix). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 04-DEC-2025 The pharmacist wanted to know how to proceed with the herpes zoster immunization series in a patient that received a late second dose of Shingrix. The vaccine administration facility was the same as primary reporter. The batch number was not provided upon follow up with the reporter.